Carnosine: antioxidant for aging and the brain (table)

Carnosine, or beta-alanylhistidine, was discovered in 1900 by Russian chemist Vladimir Gulevich and remained on the margins of interest for a hundred years. It returned to attention when it turned out that its concentration in muscles decreases with age, and the molecule itself does something that ordinary antioxidants do not: it binds reactive carbonyl groups before they damage proteins. However, many numbers surrounding this property have accumulated that are not supported by the cited works. Below you will find each study outlined separately: who conducted it, on whom, for how long, and what exactly was measured. You will also find information about which popular claims about carnosine do not arise from any of these works, although they appear in almost every commercial description.

KEY INFORMATION
• Stuerenburg and Kunze (Archives of Gerontology and Geriatrics, 1999) demonstrated that age is a significant negative predictor of free carnosine concentration in muscle; they studied neurologically ill patients and rats, not a healthy population.
• The repeated number "a drop of 63 percent between the ages of 10 and 70" does not appear in this work.
• Hipkiss et al. (2001) described the reaction of carnosine with carbonyl groups of proteins and presented it as a hypothesis, not as a clinical fact.
• The meta-analysis by Hobson et al. (Amino Acids, 2012) included 15 studies and 360 participants; the median improvement in exercise performance was 2.85 percent.

What is carnosine and why does it decrease with age?

Carnosine is a dipeptide composed of beta-alanine and L-histidine, primarily present in skeletal muscles, and in smaller amounts in the brain, heart, and kidneys. In the diet, it comes almost exclusively from meat, so plant-based diets provide it in trace amounts. The body can synthesize it on its own, but the rate of this synthesis is not constant throughout life.

Spadek z wiekiem zmierzyli Stuerenburg i Kunze (Archives of Gerontology and Geriatrics, 1999). They marked the concentration of free carnosine in muscle samples taken from patients with neuromuscular diseases and in skeletal muscles and hearts of rats of different ages. In the regression model, age proved to be a significant negative predictor of carnosine concentration in humans, and in rats of both sexes, the correlation with age was also negative and significant. Amyotrophic lateral sclerosis was separately noted: in this group, concentrations were lower than in the control.

However, the work does not provide any percentage value or age range. The number "a drop of 63 percent between the ages of 10 and 70," which most descriptions of carnosine repeat, does not come from this study. The authors link the loss of carnosine with the age-related decline in muscle mass and strength, and in the case of patients with amyotrophic lateral sclerosis with progressive denervation.

How does carnosine block protein glycation?

Glycation is a non-enzymatic attachment of sugars to proteins, leading to the formation of advanced glycation end products, or AGE for short. They damage skin collagen, endothelial cells, and the lens of the eye, and their accumulation increases with age. Carnosine acts differently here than antioxidants that scavenge free radicals.

Hipkiss i wsp. (Mechanisms of Ageing and Development, 2001) showed that carnosine reacts non-enzymatically with carbonyl groups present on proteins, and they named this process carnosinylation. Carbonyl groups accumulate on proteins with age and are responsible for cross-linking, which means sticking damaged proteins to healthy molecules. By binding to them, carnosine inhibits this cross-linking. The authors included a preliminary animal experiment: in rats fed fructose, carnosine prevented diabetes-related increases in blood pressure.

However, one must read how the authors themselves formulate the conclusion. They write that they suspect that the anti-aging effects of carnosine partly result from this reaction, and that carnosinylation could influence the fate of damaged proteins. This is a hypothesis formulated based on laboratory data. The popular statement that carnosine "reverses already formed glycation and restores the correct structure of proteins" goes much further than this work and has no basis in it.

What is known about carnosine and the brain?

The brain consumes disproportionately large amounts of oxygen relative to its mass and is rich in lipids susceptible to peroxidation, so the hypothesis about the protective role of carnosine makes sense there. However, there is little data on humans, and it comes from one small sample.

Chez i wsp. (Journal of Child Neurology, 2002) conducted an eight-week double-blind study with 31 children with autism spectrum disorders, administering 800 mg of L-carnosine daily or a placebo. No significant changes were noted in the placebo group. In the carnosine group, scores improved on the Gilliam scale, including in the behavior, socialization, and communication subscales, as well as in the Receptive One-Word Picture Vocabulary test. It is worth noting the name of this test, as Polish descriptions attribute this study to the Peabody test, which the authors did not use.

The authors themselves state that the mechanism of action of carnosine is not well understood. The trial included 31 children and lasted 8 weeks, and the results have not been replicated in a larger study. This is not an established treatment method, and the decision to administer anything to a child with developmental disorders should be made with a neurologist or child psychiatrist, not based on an article.

Does carnosine improve physical performance?

In muscle, carnosine buffers hydrogen ions produced during intense exercise, thus delaying acidosis. This mechanism has mainly been tested through beta-alanine supplementation, which is a substrate for carnosine synthesis and raises its concentration in muscle more effectively than administering the dipeptide alone.

Metaanaliza Hobsona i wsp. (Amino Acids, 2012) collected 15 published studies, encompassing 57 measurements in 23 exercise tests and 360 participants. Beta-alanine significantly improved results compared to placebo, with the improvement concerning endurance rather than athletic performance. Efforts lasting from 60 to 240 seconds performed better, as did efforts longer than 240 seconds, while there was no difference in efforts shorter than 60 seconds. The median improvement was 2.85 percent.

This is a number worth remembering when reading advertisements. Just under three percent at a median total intake of 179 grams of beta-alanine is a real but modest effect, measurable more in a laboratory than in the experience of the exerciser. The meta-analysis did not evaluate orally administered L-carnosine, only its precursor.

Does carnosine protect vision?

The lens of the eye is one of the tissues where glycation and oxidative stress are best documented, as its proteins are practically not replaced throughout life. However, the ophthalmological study concerned not oral carnosine, but its derivative administered topically.

Babizhajew i wsp. (Drugs in R&D, 2002) included a randomized study of 49 people with age-related cataracts, totaling 76 eyes, with an average age of 65 years. Twenty-six patients, or 41 eyes, received drops with one percent N-acetylcarnosine twice daily; the control group consisted of patients with placebo drops and patients not receiving drops. After six months, improvement in best-corrected visual acuity was noted in 90 percent of treated eyes, and improvement in glare sensitivity in nearly 89 percent. In the lens imaging analysis, improvement concerned 41.5 percent of eyes. The effect persisted after two years, and the tolerance of the drops was good.

Two caveats must be made immediately. The number 90 percent refers to eyes, not patients, and pertains to visual acuity, not lens transparency, for which the result was clearly lower. Moreover, N-acetylcarnosine in drops is a different preparation than oral L-carnosine. This study does not provide any information about the effect of capsules on the lens.

How does carnosine differ from beta-alanine and for whom does it make sense?

Beta-alanine is a component of carnosine, so its administration increases the pool of substrate for dipeptide synthesis directly in the tissue. Oral L-carnosine, on the other hand, is quickly broken down in the blood by carnosinase, an enzyme that cleaves it back into beta-alanine and histidine. This is why sports studies almost without exception use the precursor rather than the ready dipeptide.

Our observations from comparing these studies are as follows: the literature on carnosine and the literature on beta-alanine practically address two different questions. Studies on beta-alanine measure exercise performance in healthy individuals. Studies on carnosine measure clinical endpoints in small groups, and one of them, the ophthalmological study, does not concern oral administration at all. Commercial descriptions usually mix one with the other.

So for whom does carnosine make sense? The honest answer is: there is no study that resolves this for a healthy adult. Individuals with kidney diseases should discuss usage with a doctor, as the kidney is involved in carnosine metabolism. In a similar context, they are described ergotioneina and glutation, and a separate thread is coenzyme Q10, whose concentration also decreases with age. You can find such preparations in the category supplements.

Frequently Asked Questions

Does carnosine really drop by 63 percent with age?

This number does not come from the work it is usually attributed to. Stuerenburg and Kunze (1999) demonstrated that age is a significant negative predictor of free carnosine concentration in muscle, but they did not provide either a percentage value or an age range from 10 to 70 years.

What is the difference between carnosine and beta-alanine?

Beta-alanine is a component of carnosine and a substrate for its synthesis in tissue. Oral L-carnosine is rapidly broken down in the blood by carnosinase. The meta-analysis by Hobson et al. (2012), cited by manufacturers, evaluated beta-alanine, not the ready dipeptide administered orally.

Does carnosine reverse protein glycation?

Not in the sense that commercial descriptions claim. Hipkiss et al. (2001) demonstrated that carnosine binds to carbonyl groups of proteins and inhibits their cross-linking with normal molecules. The authors themselves present the conclusion about anti-aging action as a hypothesis requiring confirmation.

Does carnosine help children with autism?

One double-blind study involving 31 children showed improvement on the Gilliam scale and in a vocabulary test after 8 weeks at 800 mg of L-carnosine daily (Chez et al., 2002). The result was not replicated in a larger sample. This is not an accepted treatment method and requires a doctor's decision.

Do drops with carnosine treat cataracts?

The study by Babizhajev et al. (2002) involved 49 people with age-related cataracts. After 6 months, improvement in visual acuity was noted in 90 percent of treated eyes, but improvement in lens image analysis was only 41.5 percent. This refers to drops with N-acetylcarnosine, not oral capsules.

Is carnosine safe?

The cited studies did not report serious adverse effects, but involved several dozen people and lasted from 8 weeks to 2 years. This is too little to comment on long-term safety. Individuals with kidney diseases and those taking medications regularly should consult supplementation with a doctor.

This article is for informational and educational purposes and does not constitute medical advice. Before starting supplementation, consult your doctor, especially if you are taking medications regularly, are pregnant or breastfeeding, or have a chronic illness.

Author: Michał Waluk · Opublikowano: 2026-08-05 · Aktualizacja: 2026-08-11